The Biopharma Sentiment Index rose to 90 in Q1 2026, up from 78 the prior quarter, signaling a broad improvement in industry mood driven by dealmaking and capital access. The index, produced by Endpoints Signal, showed gains across business conditions, financing, regulatory outlook and hiring metrics, based on a survey of nearly 1,000 ecosystem respondents. While sentiment improved, the index remains below neutral and respondents flagged politics and pricing as primary downside risks. The report stressed that stronger deal activity and fundraising in Q4 2025 underpinned the rebound, but respondents emphasized the need for durable regulatory clarity and continued capital flow to sustain the recovery.